Erratum (DOI:10.1016/S1474-4422(06)70679-2);Peripheral nervous system involvement in patients with cancer

Lancet Neurology

Volumn 6, Issue 1, 2007, Pages 75-86

  Antoine, Jean Christophe ^a   Camdessanché, Jean Philippe ^a  

^a SERVICE DE NEUROLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BORTEZOMIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPOTHILONE DERIVATIVE; NAVELBINE; OXALIPLATIN; PACLITAXEL; SURAMIN; THALIDOMIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

AUTONOMIC DYSFUNCTION; AUTONOMIC NEUROPATHY; CANCER; CANCER DIAGNOSIS; CLINICAL TRIAL; CRANIAL NEUROPATHY; DEMYELINATING NEUROPATHY; EATON LAMBERT SYNDROME; FACIAL NERVE PARALYSIS; HUMAN; MENINGEAL METASTASIS; MONONEUROPATHY MULTIPLEX; MYELOMA; MYOKYMIA; NERVE SHEATH TUMOR; NEUROPATHY; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; PARANEOPLASTIC NEUROPATHY; PATIENT ASSESSMENT; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY;

EID: 33845294808     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70094-7     Document Type: Erratum

References (136)

1. Croft P., and Wilkinson M. The incidence of carcinomatous neuromyopathy in patients with various types of carcinoma. Brain 88 (1965) 427-434
2. Currie S., Henson R., Morgan H., and Poole A. The incidence of the non-metastatic neurological syndromes of obscure origin in the reticuloses. Brain 93 (1970) 629-640
3. Ramchandren S., and Dalmau J. Metastases to the peripheral nervous system. J Neurooncol 75 (2005) 101-110
4. Kelly J., and Karcher D. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve 31 (2005) 301-313
5. Azzarelli B., Easterling K., and Norton J. Leukemic cell-endothelial cell interactions in leukemic cell dissemination. Lab Invest 60 (1989) 45-64
6. Kern W., Spier C., Hanneman E., Miller T., Matzner M., and Grogan T. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement. Blood 79 (1992) 2432-2437
7. Mrugala M., Batchelor T., and Plotkin S. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 18 (2005) 604-610
8. Ducatman B., Scheithauer B., Piepgras D., Reiman H., and Ilstrup D. Malignant peripheral nerve sheath tumors: a clinicopathologic study of 120 cases. Cancer 57 (1986) 2006-2021
9. Foley K., Woodruff J., Ellis F., and Posner J. Radiation-induced malignant and atypical peripheral nerve sheath tumors. Ann Neurol 7 (1980) 311-318
10. Bhattacharyya A., Perrin R., and Guha A. Peripheral nerve tumors: management strategies and molecular insights. J Neurooncol 69 (2004) 335-349
11. Taillibert S., Laigle-Donadey F., Chodkiewicz C., Sanson M., Hoang-Xuan K., and Delattre J. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol 75 (2005) 85-99
12. Enting R. Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res 125 (2005) 17-30
13. Chamberlain M., Nolan C., and Abrey L. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 75 (2005) 71-83
14. Lister A., Abrey L., and Sandlund J. Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program (2002) 283-296
15. Wasserstrom W., Glass J., and Posner J. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49 (1982) 759-772
16. Kaplan J., DeSouza T., Farkash A., et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 9 (1990) 225-229
17. Straathof C., de Bruin H., Dippel D., and Vecht C. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 246 (1999) 810-814
18. Chamberlain M., Sandy A., and Press G. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40 (1990) 435-438
19. Glantz M., Cole B., Glantz L., et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82 (1998) 733-739
20. van Oostenbrugge R., Hopman A., Lenders M., et al. Detection of malignant cells in cerebrospinal fluid using fluorescence in situ hybridization. J Neuropathol Exp Neurol 56 (1997) 743-748
21. Rhodes C., Glantz M., Glantz L., et al. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 77 (1996) 543-548
22. Cheng T., O'Neill B., Scheithauer B., and Piepgras D. Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery 34 (1994) 590-595
23. Kori S., Foley K., and Posner J. Brachial plexus lesions in patients with cancer: 100 cases. Neurology 31 (1981) 45-50
24. Jaeckle K. Nerve plexus metastases. Neurol Clin 9 (1991) 857-866
25. Jaeckle K., Young D., and Foley K. The natural history of lumbosacral plexopathy in cancer. Neurology 35 (1985) 8-15
26. Thyagarajan D., Cascino T., and Harms G. Magnetic resonance imaging in brachial plexopathy of cancer. Neurology 45 (1995) 421-427
27. Taylor B., Kimmel D., Krecke K., and Cascino T. Magnetic resonance imaging in cancer-related lumbosacral plexopathy. Mayo Clin Proc 72 (1997) 823-829
28. Ahmad A., Barrington S., Maisey M., and Rubens R. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 79 (1999) 478-482
29. Hathaway P., Mankoff D., Maravilla K., et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 210 (1999) 807-814
30. Greenberg H., Deck M., Vikram B., Chu F., and Posner J. Metastasis to the base of the skull: clinical findings in 43 patients. Neurology 31 (1981) 530-537
31. Laigle-Donadey F., Taillibert S., Martin-Duverneuil N., Hildebrand J., and Delattre J. Skull-base metastases. J Neurooncol 75 (2005) 63-69
32. Morris J., and Joffe R. Perineural spread of cutaneous basal and squamous cell carcinomas: the clinical appearance of spread into the trigeminal and facial nerves. Arch Neurol 40 (1983) 424-429
33. Grisold W., Piza-Katzer H., Jahn R., and Herczeg E. Intraneural nerve metastasis with multiple mononeuropathies. J Peripher Nerv Syst 5 (2000) 163-167
34. Johnson P. Hematogenous metastases of carcinoma to dorsal root ganglia. Acta Neuropathol (Berl) 38 (1977) 171-172
35. Baehring J., Damek D., Martin E., Betensky R., and Hochberg F. Neurolymphomatosis. Neuro-oncol 5 2 (2003) 104-115
36. Kuroda Y., Nakata H., Kakigi R., Oda K., Shibasaki H., and Nakashiro H. Human neurolymphomatosis by adult T-cell leukemia. Neurology 39 (1989) 144-146
37. Odabasi Z., Parrott J., Reddy V., and Oh S. Neurolymphomatosis associated with muscle and cerebral involvement caused by natural killer cell lymphoma: a case report and review of literature. J Peripher Nerv Syst 6 (2001) 197-203
38. Trojan A., Jermann M., Taverna C., and Hany T. Fusion PET-CT imaging of neurolymphomatosis. Ann Oncol 13 (2002) 802-805
39. Kanter P., Zeidman A., Streifler J., et al. PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. Eur J Haematol 74 (2005) 66-69
40. Vallat J., De Mascarel H., Bordessoule D., et al. Non-Hodgkin malignant lymphomas and peripheral neuropathies: 13 cases. Brain 118 (1995) 1233-1245
41. Creange A., Theodorou I., Sabourin J., Vital C., Farcet J., and Gheradi R. Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia: evidence for clonal B cells within muscle and nerve. J Neurol Sci 137 (1996) 35-41
42. Nakahara T., Saito T., Muroi A., et al. Intravascular lymphomatosis presenting as an ascending cauda equina: conus medullaris syndrome: remission after biweekly CHOP therapy. J Neurol Neurosurg Psychiatry 67 (1999) 403-406
43. Darnell R., and Posner J. Paraneoplastic syndromes involving the nervous system. N Engl J Med 349 (2003) 1543-1554
44. Rudnicki S., and Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 23 (2000) 1800-1818
45. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol 1 (2002) 294-305
46. Graus F., Delattre J., Antoine J., et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75 (2004) 1135-1140
47. Kuntzer T., Antoine J., and Steck A. Clinical features and pathophysiological basis of sensory neuronopathies (ganglionopathies). Muscle Nerve 30 (2004) 255-268
48. Dalmau J., Graus F., Rosenblum M., and Posner J. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore) 71 (1992) 59-72
49. Graus F., Keime-Guibert F., Rene R., et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124 (2001) 1138-1148
50. Graus F., Bonaventura I., Uchuya M., et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 44 (1994) 2258-2261
51. Camdessanche J., Antoine J., Honnorat J., et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies: a clinical and electrophysiological study of 20 patients. Brain 125 (2002) 166-175
52. Horwich M., Cho L., Porro R., and Posner J. Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol 2 (1977) 7-19
53. Molinuevo J., Graus F., Serrano C., Rene R., Guerrero A., and Illa I. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 44 (1998) 976-980
54. Verma A., Berger J., Snodgrass S., and Petito C. Motor neuron disease: a paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma. Ann Neurol 40 (1996) 112-116
55. Younger D., Dalmau J., Inghirami G., Sherman W., and Hays A. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology 44 (1994) 181-183
56. Antoine J., Mosnier J., Honnorat J., et al. Paraneoplastic demyelinating neuropathy, subacute sensory neuropathy, and anti-Hu antibodies: clinicopathological study of an autopsy case. Muscle Nerve 21 (1998) 850-857
57. Honnorat J., Antoine J., Derrington E., Aguera M., and Belin M. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 61 (1996) 270-278
58. Yu Z., Kryzer T., Griesmann G., Kim K., Benarroch E., and Lennon V. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 49 (2001) 146-154
59. Antoine J., Honnorat J., Camdessanche J., et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 49 (2001) 214-221
60. Waragai M., Chiba A., Uchibori A., Fukushima T., Anno M., and Tanaka K. Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry 77 (2006) 111-113
61. Tracy J., Lennon V., and Pittock S. Purkinje cell antibody type 1 (PCA-1, Anti-Yo): peripheral nerve manifestations. Neurology 66 (2006) A188
62. O'Neill J., Murray N., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 111 (1988) 577-596
63. Wirtz P., Smallegange T., Wintzen A., and Verschuuren J. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 104 (2002) 359-363
64. Wirtz P., Sotodeh M., Nijnuis M., et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 73 (2002) 766-768
65. Clouston P., Saper C., Arbizu T., et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology 42 (1992) 1944-1950
66. Younes-Mhenni S., Janier M., Cinotti L., et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 127 (2004) 2331-2338
67. Hart I., Maddison P., Newsom-Davis J., Vincent A., and Mills K. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 (2002) 1887-1895
68. Newsom-Davis J., and Mills K. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 116 (1993) 453-469
69. Hart I., Waters C., Vincent A., et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41 (1997) 238-246
70. Antoine J., Mosnier J., Absi L., Convers P., Honnorat J., and Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry 67 (1999) 7-14
71. Gordon P., Rowland L., Younger D., et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology 48 (1997) 1671-1678
72. Evans B., Fagan C., Arnold T., Dropcho E., and Oh S. Paraneoplastic motor neuron disease and renal cell carcinoma: improvement after nephrectomy. Neurology 40 (1990) 960-962
73. Oh S. Paraneoplastic vasculitis of the peripheral nervous system. In: Younger D. (Ed). Vasculitis and the nervous system (1997), W B Saunders company, Philadelphia 849-863
74. Antoine J., Mosnier J., Lapras J., et al. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry 60 (1996) 188-190
75. Vigliani M., Magistrello M., Polo P., Mutani R., and Chio A. Risk of cancer in patients with Guillain-Barre syndrome (GBS): a population-based study. J Neurol 251 (2004) 321-326
76. Vernino S., Low P., Fealey R., Stewart J., Farrugia G., and Lennon V. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 343 (2000) 847-855
77. Berghs S., Ferracci F., Maksimova E., et al. Autoimmunity to beta IV spectrin in paraneoplastic lower motor neuron syndrome. Proc Natl Acad Sci USA 98 (2001) 6945-6950
78. Antoine J., Camdessanche J., Ferraud K., and Caudie C. Antiganglioside antibodies in paraneoplastic peripheral neuropathies. J Neurol Neurosurg Psychiatry 75 (2004) 1765-1767
79. Weiss M., Luciano C., Semino-Mora C., Dalakas M., and Quarles R. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology 51 (1998) 1738-1741
80. Kloos L., Sillevis Smitt P., Ang C., Kruit W., and Stoter G. Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma. J Neurol Neurosurg Psychiatry 74 (2003) 507-509
81. Kyle R., and Rajkumar S. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 194 (2003) 112-139
82. Kelly Jr. J., Kyle R., O'Brien P., and Dyck P. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol 6 (1979) 1-7
83. Kyle R., and Bayrd E. Amyloidosis: review of 236 cases. Medicine (Baltimore) 54 (1975) 271-299
84. Brouet J., Clauvel J., Danon F., Klein M., and Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 57 (1974) 775-788
85. Gemignani F., Melli G., Inglese C., and Marbini A. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst 7 (2002) 59-64
86. Levine T., Pestronk A., Florence J., et al. Peripheral neuropathies in Waldenstrom's macroglobulinaemia. J Neurol Neurosurg Psychiatry 77 (2006) 224-228
87. Baldini L., Nobile-Orazio E., Guffanti A., et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol 45 (1994) 25-31
88. Dabby R., Weimer L., Hays A., Olarte M., and Latov N. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology 54 (2000) 1448-1452
89. Kobayashi M., Kato K., Funakoshi K., Watanabe S., and Toyoshima I. Neuropathology of paraneoplastic neuropathy with anti-disialosyl antibody. Muscle Nerve 32 (2005) 216-222
90. Noguchi M., Mori K., Yamazaki S., Suda K., Sato N., and Oshimi K. Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b. Br J Haematol 123 (2003) 600-605
91. Nakanishi T., Sobue I., Toyokura Y., et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 34 (1984) 712-720
92. Dispenzieri A., Kyle R., Lacy M., et al. POEMS syndrome: definitions and long-term outcome. Blood 101 (2003) 2496-2506
93. Gherardi R., Belec L., Soubrier M., et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood 87 (1996) 1458-1465
94. Watanabe O., Maruyama I., Arimura K., et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 21 (1998) 1390-1397
95. Scarlato M., Previtali S., Carpo M., et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 128 (2005) 1911-1920
96. Vital C., Vallat J., Deminiere C., Loubet A., and Leboutet M. Peripheral nerve damage during multiple myeloma and Waldenstrom's macroglobulinemia: an ultrastructural and immunopathologic study. Cancer 50 (1982) 1491-1497
97. Kelly Jr. J., Kyle R., Miles J., O'Brien P., and Dyck P. The spectrum of peripheral neuropathy in myeloma. Neurology 31 (1981) 24-31
98. Umapathi T., and Chaudhry V. Toxic neuropathy. Curr Opin Neurol 18 (2005) 574-580
99. Quasthoff S., and Hartung H. Chemotherapy-induced peripheral neuropathy. J Neurol 249 (2002) 9-17
100. Peltier A., and Russell J. Recent advances in drug-induced neuropathies. Curr Opin Neurol 15 (2002) 633-638
101. Burns B., and Shotton J. Vocal fold palsy following vinca alkaloid treatment. J Laryngol Otol 112 (1998) 485-487
102. Lee R., Oster M., Balmaceda C., Hesdorffer C., Vahdat L., and Papadopoulos K. Bilateral facial nerve palsy secondary to the administration of high-dose paclitaxel. Ann Oncol 10 (1999) 1245-1247
103. Lee J., and Swain S. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24 (2006) 1633-1642
104. McDonald E., and Windebank A. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 9 (2002) 220-233
105. Webster R., Brain K., Wilson R., Grem J., and Vincent A. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol 146 (2005) 1027-1039
106. Kirchmair R., Walter D., Ii M., et al. Antiangiogenesis mediates cisplatin-induced peripheral neuropathy: attenuation or reversal by local vascular endothelial growth factor gene therapy without augmenting tumor growth. Circulation 111 (2005) 2662-2670
107. Chaudhry V., Eisenberger M., Sinibaldi V., Sheikh K., Griffin J., and Cornblath D. A prospective study of suramin-induced peripheral neuropathy. Brain 119 (1996) 2039-2052
108. La Rocca R., Meer J., Gilliatt R., et al. Suramin-induced polyneuropathy. Neurology 40 (1990) 954-960
109. Russell J., Gill J., Sorenson E., Schultz D., and Windebank A. Suramin-induced neuropathy in an animal model. J Neurol Sci 192 (2001) 71-80
110. Briani C., Zara G., Rondinone R., et al. Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology 62 (2004) 2288-2290
111. Chaudhry V., Cornblath D., Corse A., Freimer M., Simmons-O'Brien E., and Vogelsang G. Thalidomide-induced neuropathy. Neurology 59 (2002) 1872-1875
112. Giannini F., Volpi N., Rossi S., Passero S., Fimiani M., and Cerase A. Thalidomide-induced neuropathy: a ganglionopathy?. Neurology 60 (2003) 877-878
113. Richardson P., Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 (2006) 3113-3120
114. Freilich R., Balmaceda C., Seidman A., Rubin M., and DeAngelis L. Motor neuropathy due to docetaxel and paclitaxel. Neurology 47 (1996) 115-118
115. Wilson R., Lehky T., Thomas R., Quinn M., Floeter M., and Grem J. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20 (2002) 1767-1774
116. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30 suppl 15 (2003) 5-13
117. Chaudhry V., Chaudhry M., Crawford T., Simmons-O'Brien E., and Griffin J. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60 (2003) 337-340
118. Kalfakis N., Panas M., Karadima G., Floroskufi P., Kokolakis N., and Vassilopoulos D. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 59 (2002) 1470-1471
119. Hildebrandt G., Holler E., Woenkhaus M., et al. Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy. Ann Oncol 11 (2000) 743-747
120. Stubblefield M., Slovin S., MacGregor-Cortelli B., et al. An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clin Oncol (R Coll Radiol) 18 (2006) 410-418
121. Argyriou A., Chroni E., Koutras A., et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64 (2005) 26-31
122. Bentzen S., and Dische S. Morbidity related to axillary irradiation in the treatment of breast cancer. Acta Oncol 39 (2000) 337-347
123. Bajrovic A., Rades D., Fehlauer F., et al. Is there a life-long risk of brachial plexopathy after radiotherapy of supraclavicular lymph nodes in breast cancer patients?. Radiother Oncol 71 (2004) 297-301
124. Johansson S., Svensson H., and Denekamp J. Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. Int J Radiat Oncol Biol Phys 52 (2002) 1207-1219
125. Harper Jr. C., Thomas J., Cascino T., and Litchy W. Distinction between neoplastic and radiation-induced brachial plexopathy: with emphasis on the role of EMG. Neurology 39 (1989) 502-506
126. Qayyum A., MacVicar A., Padhani A., Revell P., and Husband J. Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques. Radiology 214 (2000) 837-842
127. Bowen J., Gregory R., Squier M., and Donaghy M. The post-irradiation lower motor neuron syndrome neuronopathy or radiculopathy?. Brain 119 (1996) 1429-1439
128. Brander P., Jarvinen V., Lohela P., and Salmi T. Bilateral diaphragmatic weakness: a late complication of radiotherapy. Thorax 52 (1997) 829-831
129. Mendes D., Nawalkar R., and Eldar S. Post-irradiation femoral neuropathy. A case report. J Bone Joint Surg Am 73 (1991) 137-140
130. Combs S., Thilmann C., Debus J., and Schulz-Ertner D. Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas. Int J Radiat Oncol Biol Phys 64 (2006) 1341-1347
131. Lin Y., Jen Y., and Lin J. Radiation-related cranial nerve palsy in patients with nasopharyngeal carcinoma. Cancer 95 (2002) 404-409
132. Coover L. Permanent iatrogenic vocal cord paralysis after I-131 therapy: a case report and literature review. Clin Nucl Med 25 (2000) 508-510
133. Marti-Fabregas J., Montero J., Lopez-Villegas D., and Quer M. Post-irradiation neuromyotonia in bilateral facial and trigeminal nerve distribution. Neurology 48 (1997) 1107-1109
134. Dreizen S., McCredie K., Bodey G., and Keating M. Mucocutaneous herpetic infections during cancer chemotherapy. Postgrad Med 84 (1988) 181-184
135. Graus F., Ferrer I., and Lamarca J. Mixed carcinomatous neuropathy in patients with lung cancer and lymphoma. Acta Neurol Scand 68 (1983) 40-48
136. Koehler P., Buscher M., Rozeman C., Leffers P., and Twijnstra A. Peroneal nerve neuropathy in cancer patients: a paraneoplastic syndrome?. J Neurol 244 (1997) 328-332